MSB 1.86% $1.32 mesoblast limited

Tracking Valuations, page-131

  1. 11,249 Posts.
    lightbulb Created with Sketch. 29638
    As an aside to valuations, it is worth noting the revenue growth potential of biotech products.

    I looked into the annual revenue growth of Keytruda (a cancer drug) for a biotech investment the other day.

    This is what I found going through the annual filings for Merck:
    • 2015: USD $566M (launch year)
    • 2016: USD $1,402M (YoY growth 248%)
    • 2017: USD $3,809M (YoY growth 272%)
    • 2018: USD $7,171M (YoY growth 188%)
    • 2019: USD $11,084M (YoY growth 155%)
    So that is average annual revenue growth for this new cancer drug 216%.

    When you consider the rollout of remestemcel-l to regions outside the US you can see how quite dramatic growth could be achieved.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.32
Change
-0.025(1.86%)
Mkt cap ! $1.507B
Open High Low Value Volume
$1.35 $1.35 $1.31 $2.699M 2.040M

Buyers (Bids)

No. Vol. Price($)
2 34995 $1.32
 

Sellers (Offers)

Price($) Vol. No.
$1.33 10374 2
View Market Depth
Last trade - 16.10pm 31/10/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.